2019 Texas Oncology Clinical Educational Symposium

2.50 CME
150 MINS
$0 FEE
SAVE
J871

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc.


Target Audience

The intended audience for this activity is hematologist-oncologists, oncologists, and other health care professionals involved in the treatment of patients with cancer.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Perform appropriate testing for patients with non-small–cell lung cancer (NSCLC) to ensure optimal clinical decision-making. 
  • Select treatment for patients with anaplastic lymphoma kinase (ALK)-mutated NSCLC based on the latest clinical evidence. 
  • Examine the mechanisms underlying resistance to ALK inhibitor therapy and the resultant clinical implications for the patient. 
  • Individualize treatment for patients with multiple myeloma (MM) based on the latest clinical evidence as well as patient and disease characteristics. 
  • Identify patients with MM who may benefit from first-line stem cell transplant versus pharmacotherapy. 
  • Review the evolving role of chimeric antigen receptor (CAR)-T therapy for patients with MM. 
  • Select treatment for patients with chronic lymphocytic leukemia based on the latest clinical evidence as well as individual patient and disease characteristics. 
  • Select treatment for patients with advanced hormone receptor (HR)+/human epidermal growth factor receptor (HER)2- breast cancer based on the latest clinical evidence. 
  • Assess the latest evidence regarding the use of phosphoinositide 3-kinase (PI3K) inhibitors for subsets of patients with HR+/HER2- advanced breast cancer. 
  • Evaluate the latest clinical evidence regarding the use of immunotherapy and combination regimens for the management of patients with advanced triple-negative breast cancer.

Faculty

David Andorsky, MD
Rocky Mountain Cancer Centers 
Boulder, CO

Giada Bianchi, MD
Instructor in Medicine, Harvard Medical School 
Associate Director, Amyloidosis Program 
Dana Farber Cancer Institute 
Boston, MA

Joyce O'Shaughnessy, MD 
Celebrating Women Chair in Breast Cancer Research 
Director, Breast Cancer Research Program 
Baylor University Medical Center 
Dallas, TX

Alex Spira, MD, PhD 
Director, VCS Research Institute 
Virginia Cancer Specialists 
Medical Director, Inova Thoracic Oncology Program 
Inova Fairfax Hospital 
Fairfax, VA


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, June 28, 2019, to June 27, 2020.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 8 out of 11 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™.


MIPS Qualifying Activity

Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the Merit-Based Incentive Payment System (MIPS) of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of
    the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.


Faculty reports the following relationships

David Andorsky, MD
Consulting Fee: Celgene
Contracted Research: AstraZeneca

Giada Bianchi, MD
No relevant financial relationships to disclose.

Joyce O'Shaughnessy, MD 
Consulting Fee: AstraZeneca, Celgene, Eisai, Genentech, Lilly, Novartis, Pfizer, Seattle Genetics
Speakers Bureau: AstraZeneca, Lilly, Novartis

Alex Spira, MD, PhD 
Contracted Research: Ariad/Takeda, Pfizer, Roche


Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.


Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com